We are live on ! Find out more
ECM

Endurant Capital Management Portfolio holdings

AUM $17.4M
1-Year Est. Return 7.38%
This Fund
S&P 500
This Quarter Est. Return
-3.73%
1 Year Est. Return
+7.38%
3 Year Est. Return
+18.38%
5 Year Est. Return
+100.61%
10 Year Est. Return
–
AUM
$279M
AUM Growth
+$25M
Cap. Flow
-$440M
Cap. Flow %
-158.03%
Top 10 Hldgs %
59.15%
Holding
68
New
18
Increased
13
Reduced
17
Closed
19

Top Buys

Rank Stock Value
1
RCM
R1 RCM Inc. Common Stock
RCM
+$18.3M
2
JNJ icon
Johnson & Johnson
JNJ
+$14.2M
3
HCA icon
HCA Healthcare
HCA
+$13.7M
4
CRL icon
Charles River Laboratories
CRL
+$10.1M
5
BMY icon
Bristol-Myers Squibb
BMY
+$9.66M

Top Sells

Rank Stock Value
1
TAK icon
Takeda Pharmaceutical
TAK
+$14.5M
2
IRTC icon
iRhythm Holdings
IRTC
+$8.18M
3
AVDR
Avedro, Inc Common Stock
AVDR
+$7.03M
4
HUM icon
Humana
HUM
+$6.7M
5
EHC icon
Encompass Health
EHC
+$6.5M

Sector Composition

Rank Sector Weight
1 Healthcare 76.68%
2 Industrials 7.62%
3 Technology 0.51%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ACRS icon
26
Aclaris Therapeutics
ACRS
$726M
$1.91M 0.69%
1,769,785
+140,458
+9% +$199K
INSP icon
27
Inspire Medical Systems
INSP
$1.45B
$1.88M 0.67%
+30,805
New +$2.03M
SDC
28
DELISTED
SmileDirectClub, Inc. Class A Common Stock
SDC
$1.85M 0.66%
+133,388
New +$2.23M
LAB icon
29
Standard BioTools
LAB
$340M
$1.83M 0.66%
+395,701
New +$3.12M
TAK icon
30
Takeda Pharmaceutical
TAK
$54.6B
$1.59M 0.57%
92,273
-840,694
-90% -$14.5M
IOVA icon
31
Iovance Biotherapeutics
IOVA
$1.82B
$1.57M 0.56%
86,069
-87,169
-50% -$1.93M
IIN
32
DELISTED
IntriCon Corporation
IIN
$1.43M 0.51%
73,543
-316,252
-81% -$6.11M
AZN icon
33
AstraZeneca
AZN
$263B
$1.38M 0.5%
15,516
-46,914
-75% -$4.07M
CNMD icon
34
CONMED
CNMD
$1.39B
$1.26M 0.45%
+13,112
New +$1.23M
LQDA icon
35
Liquidia Corp
LQDA
$7.48B
$1.13M 0.41%
317,993
-150,988
-32% -$893K
HUM icon
36
Humana
HUM
$43.7B
$997K 0.36%
3,899
-23,898
-86% -$6.7M
PETQ
37
DELISTED
PetIQ, Inc. Class A Common Stock
PETQ
$936K 0.34%
+34,354
New +$1.09M
ATRC icon
38
AtriCure
ATRC
$1.92B
$858K 0.31%
34,391
-184,647
-84% -$5.27M
EHC icon
39
Encompass Health
EHC
$11B
$753K 0.27%
14,948
-129,357
-90% -$6.5M
AXNX
40
DELISTED
Axonics, Inc. Common Stock
AXNX
$747K 0.27%
+27,759
New +$967K
ACHC icon
41
Acadia Healthcare
ACHC
$2.76B
$743K 0.27%
+23,918
New +$728K
PRTA icon
42
Prothena Corp
PRTA
$425M
$677K 0.24%
+86,407
New +$768K
XENT
43
DELISTED
Intersect ENT, Inc
XENT
$643K 0.23%
37,815
-232,746
-86% -$4.24M
GNCA
44
DELISTED
Genocea Biosciences, Inc.
GNCA
$546K 0.2%
188,128
-101,586
-35% -$347K
APLS
45
DELISTED
Apellis Pharmaceuticals
APLS
$537K 0.19%
+22,281
New +$613K
NTGN
46
DELISTED
Neon Therapeutics, Inc. Common Stock
NTGN
$332K 0.12%
193,052
-272,598
-59% -$829K
ATNM icon
47
Actinium Pharmaceuticals
ATNM
$26.3M
$311K 0.11%
45,139
-37,573
-45% -$262K
ADVM
48
DELISTED
Adverum Biotechnologies
ADVM
– –
-3,187
Closed -$379K
ALGN icon
49
Align Technology
ALGN
$12.1B
– –
-1,962
Closed -$537K
DVA icon
50
DaVita
DVA
$15.4B
– –
-32,566
Closed -$1.83M
1
2
3

Similar funds

VAFP
Vahanian & Associates Financial Planning Saratoga Springs, New York $25.3M AUM 39.42% 1-Year Est. Return
CA
Corriente Advisors Fort Worth, Texas $9.53M AUM 805.26% 1-Year Est. Return
SCM
Somerset Capital Management London, United Kingdom $8.12M AUM 21.3% 1-Year Est. Return
FWM
Fiat Wealth Management Wayzata, Minnesota $7.9M AUM
TOPU
Trustees of Princeton University Princeton, New Jersey $7.77M AUM
CCMU
Cheyne Capital Management (UK) London, United Kingdom $27.9M AUM 36.14% 1-Year Est. Return
TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
HSCU
Half Sky Capital (UK) London, United Kingdom $30.5M AUM 67.32% 1-Year Est. Return

Endurant Capital Management's Q3 2019 Portfolio in Review

As of Q3 2019, Endurant Capital Management held 68 positions worth $279M, up 9.9% from $254M the previous quarter. Its ten largest holdings account for 59% of the portfolio.

Endurant Capital Management withdrew a net $440M in Q3 2019, closing 19 positions and reducing 17 holdings. Its most notable exit was iRhythm Holdings, an estimated $8.18M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 77% of assets, down from 77% a quarter earlier, followed by Industrials and Technology.

Against the trend, Endurant Capital Management opened a new position in Johnson & Johnson worth $13.9M.

  • Endurant Capital Management's largest Q3 2019 buy was Johnson & Johnson: 107,413 shares worth $13.9M.
  • Endurant Capital Management added most to R1 RCM Inc. Common Stock in Q3 2019, an estimated $18.3M increase.
  • Endurant Capital Management's biggest Q3 2019 reduction was Takeda Pharmaceutical, cutting an estimated $14.5M.
  • Endurant Capital Management fully exited iRhythm Holdings in Q3 2019, selling an estimated $8.18M.
  • Endurant Capital Management's ten largest holdings make up 59% of its $279M portfolio in Q3 2019.
  • Endurant Capital Management opened 18 new positions and closed 19 in Q3 2019.
  • Endurant Capital Management's portfolio value rose 9.9% quarter-over-quarter to $279M.

Based on Endurant Capital Management's 13F filing for Q3 2019, filed 14 Nov 2019.